The use of fenofibrate in the prevention of diabetic retinopathy progression: an interdisciplinary consensus

Preiss D, Logue J, Sammons E et al. Effect of Fenofibrate on Progression of Diabetic Retinopathy. NEJM Evid 2024; 3(8): EVIDoa2400179. Dostupné z DOI: <http://dx.doi.org/10.1056/EVIDoa2400179>.

Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370(9600): 1687–1697. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(07)61607–9>.

Ginsberg HN, Elam MB, Lovato LC et al. [ACCORD Study Group]. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1563–1574. Dostupné z DOI: <http://dx.doli.org/10.1056/NEJMoa1001282>.

Chew EY, Ambrosius WT, Davis MD et al. [ACCORD Study Group and ACCORD Eye Study Group]. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. N Engl J Med 2010; 363(3): 233–244. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1001288>.

Morgan CL, Owens DR, Aubonnet P et al. Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study. BMJ Open 2013; 3(12): e004025. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjopen-2013–004025>.

Lin YC, Chen YC, Horng JT et al. Association of Fenofibrate and Diabetic Retinopathy in Type 2 Diabetic Patients: A Population-Based Retrospective Cohort Study in Taiwan. Medicina (Kaunas) 2020; 56(8): 385. Dostupné z DOI: <http://dx.doi.org/10.3390/medicina56080385>.

Meer E, Bavinger JC, Yu Y et al. Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy. JAMA Ophthalmol 2022; 140(5): 529–532. Dostupné z DOI: <http://dx.doi.org/10.1001/jamaophthalmol.2022.0633>.

Kim NH, Choi J, Kim YH et al. Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensity-matched cohort study. Diabetes Metab 2023; 49(3): Dostupné z DOI: <http://dx.doi.org/101428.10.1016/j.diabet.2023.101428>.

Preiss D, Spata E, Holman RR et al. Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials. Diabetes Care 2022; 45(1): e1-e2. Dostupné z DOI: <http://dx.doi.org/10.2337/dc21–1439>.

Lipanthyl. Souhrn údajů o léčivém přípravku. Dostupné z WWW: <www.sukl.cz>.

Noonan JE, Jenkins AJ, Ma JX et al. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes 2013; 62(12): 3968–3975. Dostupné z DOI: <http://dx.doi.org/10.2337/db13–0800>.

The Royal College of Ophthalmologists. Diabetic Retinopathy Guidelines December 2012. Dostupné z WWW: <https://www.rcophth.ac.uk/wp-content/uploads/2021/08/2012-SCI-267-Diabetic-Retinopathy-Guidelines-December-2012.pdf>.

Solomon SD, Chew E, Duh EJ et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017; 40(3): 412–418. Dostupné z DOI: <http://dx.doi.org/10.2337/dc16–2641>. Erratum in Erratum. Solomon SD, Chew E, Duh EJ, Sobrin L et al. Diabetes Care 2017; 40(6): 809. Dostupné z DOI: <http://dx.doi.org/10.2337/dc17-er06e>. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017; 40: 412–418. Solomon SD, Chew E, Duh EJ et al. Diabetes Care 2017; 40(9):1285. Dostupné z DOI: <http://dx.doi.org/10.2337/dc17-er09>.

[American Diabetes Association Professional Practice Committee]. American Diabetes Association. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes – 2024. Diabetes Care 2024; 47(Suppl. 1): S231–S243. Dostupné z DOI: <http://dx.doi.org/10.2337/dc24-S012>.

Wong TY, Sun J, Kawasaki R et al. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology 2018; 125(10): 1608–1622. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ophtha.2018.04.007>.

Schmidt-Erfurth U, Garcia-Arumi J, Bandello F et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 2017; 237(4): 185–222. Dostupné z DOI: <http://dx.doi.org/U10.1159/000458539>.

Diabetic retinopathy: management and monitoring. NICE guideline [NG242]. Publikováno 13. srpna 2024. Dostupné na WWW: <https://www.nice.org.uk/guidance/ng242>.

Brownrigg JR, Hughes CO, Burleigh D et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 2016; 4(7): 588–597. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(16)30057–2>.

Pelikánová T, Kvapil T, Škrha J za ČDS, Kalvodová B, Sosna T, Ernest J et al za ČOS a ČVRS. Doporučené postupy pro diagnostiku a léčbu diabetické retinopatie. DMEV 2016; 19(2).

ČDS. Stanovisko České diabetologické společnosti ČLS JEP k vyšetření diabetické retinopatie pomocí počítačové analýzy digitálních snímků sítnice. Dostupné z WWW: <https://www.diab.cz/standardy>.

Studnička J, Němčanský J, Vysloužilová D et al. Doporučené postupy diagnostiky a léčby diabetické retinopatie. Čes a Slov Oftal 2023; 79(5): 238–247. Dostupné z WWW: <https://www.cvrs.cz/dokumenty/DoporucenePostupyDR.pdf>.

Klein BE, Myers CE, Howard KP et al. Serum Lipids and Proliferative Diabetic Retinopathy and Macular Edema in Persons With Long-term Type 1 Diabetes Mellitus: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. JAMA Ophthalmol 2015 May; 133(5): 503–510. Dostupné z DOI: <http://dx.doi.org/10.1001/jamaophthalmol.2014.5108>.